6541.TW

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$1.1B	+166.2%	$-5.10	$-5.10–$-5.10	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 5 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-12	$-1.67	$-1.44	+13.5%
2026-05-13	$-1.64	$-1.64	+0.0%
2026-03-04	$-0.76	$-1.60	-111.9%
2025-11-06	$-6.53	$-1.08	+83.5%
2025-08-14	$-1.18	$-1.43	-20.8%
2025-05-07	$-1.39	$-2.09	-50.9%
2025-03-14	$-1.88	$-1.69	+9.9%
2024-11-12	$-2.19	$-1.94	+11.6%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
6541.TWTanvex BioPharma, Inc.	$30.55	+0.83%	$8.1B	—
1789.TWScinoPharm Taiwan, Ltd.	$18.15	+0.28%	$14.4B	—
3705.TWYungShin Global Holding Corporation	$56.00	+0.00%	$14.9B	—
4104.TWExcelsior Medical Co., Ltd.	$71.90	+0.28%	$13.5B	—
4162.TWOPharmaEngine, Inc.	$54.60

Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medicines, with its operations spanning Taiwan and the United States. Its core mission involves developing biosimilars aimed at treating severe conditions like neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's robust product portfolio includes TX01 and TX-05, both of which have successfully completed Phase III clinical trials. Additionally, TX-04 and TX-16 are currently undergoing Phase I clinical trials, while TX-52 and other potential therapies are in the pre-clinical development stage.

www.tanvex.com

Employees: 215
IPO / List date: Aug 13, 2015
HQ: KY

Held by traders on TradeandTell

No one on the platform currently holds 6541.TW.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in 6541.TW as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded 6541.TW yet.